Abstract

Haemonetics will report fiscal results on May 7, 2026 Pre-Market, with current-quarter consensus pointing to modest year-over-year growth in revenue and earnings while investors assess contributions from newly cleared and expanded devices and recent portfolio additions.

Market Forecast

The market currently expects Haemonetics to deliver approximately 336.86 million US dollars in revenue this quarter, up 2.27% year over year, with adjusted EPS around 1.27, up 4.24%, and EBIT near 90.71 million US dollars, up 6.73%; guidance or consensus for gross margin and net margin has not been indicated. Management’s operating focus centers on execution in hospital products and services and on newer procedural indications, while the product pipeline suggests incremental mix benefits; the most promising near-term product area is the hospital portfolio that includes vascular closure solutions, supported by recent label expansion, with last quarter segment revenue of 143.50 million US dollars and overall company revenue down 2.75% year over year.

Last Quarter Review

Haemonetics reported revenue of 338.97 million US dollars last quarter (down 2.75% year over year), gross profit margin of 59.69%, GAAP net profit attributable to shareholders of 44.74 million US dollars, net profit margin of 13.20%, and adjusted EPS of 1.31 (up 10.08% year over year). One notable financial highlight was quarter-on-quarter acceleration in bottom-line performance, with net profit rising 15.66% sequentially, reflecting product mix, scale efficiencies, and disciplined cost execution. Main business revenue mix included hospital products and services at 143.50 million US dollars, plasma products and services at 138.91 million US dollars, and blood center at 56.56 million US dollars; segment-level year-over-year changes were not separately disclosed in the summary figures.

Current Quarter Outlook

Hospital products and services

Within hospital products and services, Haemonetics is positioned to benefit from the United States Food and Drug Administration’s recent expansion of labeling for VASCADE MVP XL to accommodate larger sheath sizes for additional electrophysiology and structural heart procedures. This broadens the procedural footprint into cases that use 10–14F inner-diameter and up to 17F outer-diameter sheaths, increasing addressable usage within electrophysiology labs and structural heart programs. As these procedures scale through calendar 2026, utilization of closure systems typically drives attractive margin contribution per case, supporting profitability alongside revenue gains where adoption accelerates. From a quarter-to-quarter perspective, the company’s hospital revenue base of 143.50 million US dollars last quarter sets a reference point for mix-sensitive growth. The label expansion, validated by clinical data showing no major or minor closure-related complications in the study sample, enhances physician confidence and could support share-of-wallet gains among cardiology programs adopting pulsed field ablation and left atrial appendage closure. Given the lack of explicit gross-margin guidance this quarter, investors are likely to monitor product mix for this segment as a key indicator: higher procedural throughput and greater penetration in larger-sheath cases would be expected to lift contribution margin without requiring a proportional increase in operating expense. Operationally, commercial execution, training, and supply throughput will influence quarterly cadence. Stronger case volumes typically exhibit seasonality and scheduling dynamics, but the expanded indication is an incremental catalyst that helps offset variability. Against the prior quarter’s 338.97 million US dollars in total revenue, the consensus of 336.86 million US dollars suggests a modest sequential step-down that is consistent with normal intra-year patterns; within that, hospital products and services are poised to benefit from label-driven demand and broader account coverage, providing a counterbalance to softer areas and sustaining earnings quality.

Plasma products and services

The plasma franchise enters this quarter with a procedural and technology tailwind following the February 2026 FDA 510(k) clearance for the NexSys Plasma Collection System with Persona PLUS technology. Persona PLUS is designed to enhance donor-level optimization, which can improve yield consistency and the efficiency metrics that plasma collection centers track to manage cost per liter and throughput per bed. Technology enhancements in apheresis systems typically provide a path to more stable operations, and as Persona PLUS rolls across customer sites, it can drive incremental kit pull-through and service revenue. Last quarter, plasma products and services revenue was 138.91 million US dollars, providing a substantial base for incrementality from adoption. Management has not provided a discrete gross margin target for this quarter, yet the plasma portfolio historically benefits from a recurring disposable dynamic, where increased system utilization supports relatively durable revenue streams. The consensus outlook for this quarter—revenue of 336.86 million US dollars and adjusted EPS of 1.27—implies modest year-over-year growth for the company overall, and realization of plasma technology upgrades can be a differentiator that helps the company execute near the high end of revenue and earnings ranges if adoption proceeds smoothly. Execution risks are normal for rollouts of new system capabilities—training, workflow integration, and feedback from high-volume centers can affect the pace of deployment. However, the clearance and the underlying data support early-stage credibility, and near-term visibility into ordering trends and installations will be key data points investors look for when management updates on May 7, 2026. In combination with hospital momentum, plasma adoption contributes to the company’s earnings algorithm by balancing procedural revenue in hospitals with recurring disposables in plasma, and the EBIT estimate implies a 6.73% year-over-year increase, consistent with operating leverage from such mix.

Stock price drivers this quarter

Three tangible developments are likely to shape how the stock trades around this print. First, product catalysts: the expanded VASCADE MVP XL labeling and the cleared Persona PLUS features are both new in the period, so intra-quarter commentary on utilization, stocking orders, and initial customer feedback will be crucial. Second, integration and portfolio expansion: management completed the acquisition of Vivasure Medical Limited on January 9, 2026, adding complementary large-hole closure capabilities that can broaden longer-term vascular solutions; investors will look for timeline clarity on clinical and commercial milestones, and for commentary on any early cross-selling or operational synergies. Third, earnings quality and margin trajectory: while the company did not provide a current-quarter gross or net margin forecast, consensus implies a 4.24% year-over-year increase in adjusted EPS, and the last quarter’s 59.69% gross margin provides a baseline; investors will scrutinize pricing, manufacturing yields, and mix effects to gauge how durable any margin expansion could be through fiscal 2026. Putting these elements together, the quarter’s central question is whether the revenue cadence and margin mix can deliver above-consensus EPS given a revenue outlook that is only modestly higher year over year. If adoption curves for hospital and plasma enhancements prove supportive, the EBIT outlook of roughly 90.71 million US dollars and the EPS estimate of 1.27 look achievable with potential upside from mix. Conversely, if the ramp pace is slower or if mix shifts unfavorably, results may cluster near the midpoint of expectations, making management’s qualitative commentary on order pipelines and backlog a determinant of the immediate stock reaction.

Analyst Opinions

Across opinions captured between January 1, 2026 and April 30, 2026, the balance is predominantly bullish. We observed buy-side reaffirmations during the period, including a reiterated Buy rating with an 84 US dollars price target from BTIG, reflecting confidence in execution and in new product catalysts in both hospital and plasma. No contrary (bearish) viewpoints with specific forecasts surfaced in our captured window, producing a bullish-to-bearish ratio of 100% to 0%. The bullish arguments emphasize several themes. Analysts cite the FDA clearance for the NexSys Plasma Collection System with Persona PLUS as a concrete near-term growth lever, given the potential for improved donor management and throughput efficiencies that can enhance disposable utilization. They also highlight the expanded labeling for VASCADE MVP XL in more complex electrophysiology and structural heart procedures, which increases the practical clinical footprint and supports higher procedure-based penetration in hospital accounts. With adjusted EPS expected to rise 4.24% year over year and EBIT projected to grow 6.73% year over year, the earnings setup is viewed as balanced, with upside contingent on the pace of uptake and mix in higher-contribution product lines. Bullish commentary also focuses on portfolio breadth and longer-term optionality following the January 2026 completion of the Vivasure acquisition, framing it as a strategically coherent addition to the vascular closure franchise that can expand the solution set once development and commercial plans progress. In the near term, analysts expect management’s commentary to center on adoption metrics and early commercial traction for the newly cleared and newly expanded products, while longer-term discussions may pivot to integration milestones and contribution timelines. With last quarter’s net profit margin at 13.20% and sequential net profit growth of 15.66%, the market views the company’s cost structure and mix as supportive of the earnings profile entering this report. In sum, the tracked institutions lean bullish heading into May 7, 2026. Their case rests on the intersection of product catalysts that can lift volumes and margin mix, a visible adjusted EPS growth trajectory in the mid-single-digit range year over year, and a revenue base that, while only modestly higher than a year ago, is benefiting from strategic approvals and label expansions. As a result, the majority view expects Haemonetics to meet or slightly exceed the revenue estimate of 336.86 million US dollars and to deliver adjusted EPS around or above 1.27, with management’s qualitative color on adoption and pipeline pacing serving as the key determinant for post-earnings sentiment.